Hospital
Robert Packer Hospital
Robert Packer Hospital was paid $13.81M by Medicaid between Jan 2018 and Dec 2024, across 212 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoROBERT PACKER HOSPITAL
SAYRE, PA 18840
SAYRE, PA 18840
33aNPI1083614382assigned 07/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.81M
24GClaims310,234
24DCodes billed212
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#23 of 154
Median peer was paid$2.82M
This provider vs. median4.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,890 | $154K | |
| 2019 | 11,081 | $447K | |
| 2020 | 39,139 | $1.81M | |
| 2021 | 81,711 | $3.45M | |
| 2022 | 62,539 | $3.01M | |
| 2023 | 70,263 | $3.18M | |
| 2024incomplete | 42,611 | $1.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 27,817 | 24,951 | $2.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 17,259 | 15,625 | $1.97M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 8,568 | 8,070 | $1.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.9% | 2,950 | 2,875 | $951K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 8,450 | 7,845 | $648K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.2% | 1,155 | 1,133 | $585K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 3,181 | 2,880 | $540K |
| 80053 | Comprehensive metabolic panel | 2.9% | 16,341 | 13,629 | $407K |
| G0378 | Hospital observation service, per hour | 2.8% | 1,297 | 1,078 | $381K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 2,367 | 1,717 | $313K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,461 | 1,428 | $311K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.3% | 849 | 832 | $176K |
200 more codes
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.3% | 289 | $174K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,039 | $165K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 21,790 | $149K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 609 | $141K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 224 | $136K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 943 | $120K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,071 | $119K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,130 | $102K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,786 | $98K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,705 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,054 | $92K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,051 | $83K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,393 | $81K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,174 | $81K |
| 93975 | <1% | 228 | $80K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,738 | $80K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 915 | $79K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 648 | $75K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 380 | $73K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,611 | $72K |
| 76830 | Ultrasound, transvaginal | <1% | 705 | $71K |
| 86850 | <1% | 2,178 | $69K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 999 | $65K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,983 | $59K |
| 73564 | <1% | 1,082 | $57K | |
| 73610 | <1% | 1,346 | $56K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,717 | $55K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,523 | $55K |
| 97597 | <1% | 819 | $55K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,612 | $52K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 513 | $50K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,260 | $43K |
| 73630 | <1% | 1,366 | $42K | |
| 86900 | <1% | 2,193 | $42K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 134 | $41K |
| 97161 | <1% | 430 | $39K | |
| 73110 | <1% | 1,053 | $38K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,818 | $37K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 402 | $36K |
| 83880 | <1% | 1,160 | $35K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 81 | $34K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 24 | $33K |
| 73130 | <1% | 911 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,973 | $26K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 172 | $26K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,088 | $26K |
| 84484 | <1% | 4,735 | $25K | |
| 73030 | <1% | 729 | $25K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 527 | $24K |
| 76642 | <1% | 331 | $23K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 351 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 122 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,794 | $20K |
| 80050 | General health panel | <1% | 374 | $20K |
| 87631 | <1% | 191 | $20K | |
| 83605 | <1% | 2,014 | $20K | |
| 84703 | <1% | 2,855 | $20K | |
| 76536 | <1% | 174 | $17K | |
| 94060 | <1% | 88 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 150 | $16K |
| 83690 | <1% | 4,066 | $16K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 363 | $15K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 111 | $14K |
| 43235 | <1% | 24 | $14K | |
| 87040 | <1% | 1,471 | $14K | |
| 83735 | <1% | 3,518 | $13K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,097 | $13K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 65 | $13K |
| 81025 | <1% | 2,187 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 41 | $12K |
| 85027 | <1% | 1,789 | $11K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $11K |
| 76801 | <1% | 103 | $11K | |
| 97162 | <1% | 110 | $10K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 164 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,916 | $9K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 104 | $9K |
| 73502 | <1% | 286 | $9K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 336 | $8K |
| C1769 | Guide wire | <1% | 306 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,763 | $8K |
| 90863 | <1% | 346 | $7K | |
| 86901 | <1% | 404 | $7K | |
| 82962 | <1% | 3,789 | $7K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 38 | $6K |
| 81001 | <1% | 4,273 | $6K | |
| 96376 | <1% | 602 | $6K | |
| 95886 | <1% | 155 | $6K | |
| 96367 | <1% | 86 | $6K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 81 | $6K |
| 85730 | <1% | 1,233 | $5K | |
| 86140 | <1% | 1,136 | $5K | |
| 74018 | <1% | 74 | $5K | |
| 85610 | <1% | 1,880 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $4K |
| 12001 | <1% | 14 | $4K | |
| 95816 | <1% | 24 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 441 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 642 | $4K |
| V2632 | Posterior chamber intraocular lens | <1% | 112 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 176 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 64 | $4K |
| 81003 | <1% | 2,672 | $3K | |
| 84702 | <1% | 215 | $3K | |
| 71250 | <1% | 42 | $3K | |
| 76770 | <1% | 12 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 76 | $3K |
| 73590 | <1% | 116 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $3K |
| 85378 | <1% | 292 | $3K | |
| 88304 | <1% | 140 | $3K | |
| 59025 | Fetal non-stress test | <1% | 64 | $3K |
| 73080 | <1% | 87 | $2K | |
| 88342 | <1% | 41 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 76 | $2K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 217 | $2K |
| 72110 | <1% | 43 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,120 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,876 | $2K |
| 87186 | <1% | 267 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 30 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 822 | $1K |
| 94729 | <1% | 53 | $1K | |
| 87641 | <1% | 58 | $1K | |
| 87205 | <1% | 316 | $1K | |
| 80143 | <1% | 561 | $1K | |
| 90715 | <1% | 36 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 543 | $1K |
| 80179 | <1% | 542 | $994.54 | |
| 95806 | <1% | 21 | $987.33 | |
| 85651 | <1% | 348 | $884.43 | |
| 97165 | <1% | 12 | $881.29 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,440 | $805.01 |
| 88307 | <1% | 13 | $757.62 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 122 | $729.10 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,847 | $711.23 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,285 | $668.52 |
| 73140 | <1% | 14 | $658.75 | |
| 73560 | <1% | 16 | $631.80 | |
| 87468 | <1% | 18 | $626.44 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,468 | $563.66 |
| 87075 | <1% | 86 | $484.02 | |
| 93971 | <1% | 12 | $462.50 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,350 | $415.89 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,397 | $402.28 |
| 96523 | <1% | 29 | $389.60 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,580 | $386.93 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,150 | $386.02 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $379.80 |
| 87640 | <1% | 12 | $349.96 | |
| 85014 | <1% | 76 | $349.06 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 368 | $348.57 |
| 87469 | <1% | 18 | $313.32 | |
| 87484 | <1% | 18 | $313.32 | |
| 87478 | <1% | 18 | $313.32 | |
| 73562 | <1% | 25 | $276.67 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,146 | $244.91 |
| 87176 | <1% | 55 | $231.65 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $220.75 |
| 84100 | <1% | 48 | $195.15 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 403 | $185.70 |
| 82805 | <1% | 15 | $161.73 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,012 | $132.00 |
| J3490 | Unclassified drugs | <1% | 244 | $126.90 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 711 | $112.69 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 184 | $111.58 |
| 99153 | Mod sedat endo service >5yrs | <1% | 12 | $110.90 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 124 | $107.49 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 625 | $102.13 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 412 | $99.58 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17 | $89.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 561 | $87.51 |
| 94618 | <1% | 12 | $83.63 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 27 | $68.74 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 64 | $47.18 |
| 87077 | <1% | 42 | $37.98 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 307 | $33.94 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 307 | $33.75 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 842 | $30.43 |
| 85007 | <1% | 14 | $23.43 | |
| 85018 | <1% | 19 | $22.32 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 117 | $17.80 |
| 85652 | <1% | 16 | $15.06 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 342 | $2.69 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 516 | $0.09 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 315 | $0.04 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 335 | $0.00 |
| 86618 | 0% | 20 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 41 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 19 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 62 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 16 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 108 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 32 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 18 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 41 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACAFEE, FRANCIS (VP, CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Corning Hospital | Corning, NY | $17.73M |
| Robert Packer Hospital | Towanda, PA | $1.93M |
| Troy Community Hospital Incorporated | Troy, PA | $1.10M |
| Robert Packer Hospital | Towanda, PA | $816K |
| Guthrie Towanda Memorial Hospital | Towanda, PA | $192K |
| Robert Packer Hospital | Sayre, PA | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.